Çocuklardaki tedaviye dirençli konvülziyonlarda yeni antiepileptik ilaçlar

KAYNAKLAR
Haslam
RH
A Infantile Spasms Behrman RE.
Textbook of Pediatrics. Philadelphia \VB
Saunders company 1992:1494-5
Farrel K.
Classifyin
g epileptic syndromes
Neurology I 993;43< Suppl.5) 8-1 1
Aıcardi
J
Early myoclonic encephalopathy In
Roger J. Bureau M. Dravet Ch. et all.eds
Epileptic syndromes in infancy, childhood and
adolescence 2nd ed London: John Libbey &
Company Ltd: 1992:13-21
Dravet C, Bureau M. Roger J Benign myoclonic epilepsy in infants In Roger J. Bureau M. Dravet Ch. et al. eds. Epileptic syndromes in infancy, childhood and adolescence 2nd ed London John Libbey & Company 1992:07-74 Dravet J, Bureau M. Guerrini R, et al Severe myoclonic epilepsy in infants In: Roger J. Bureau M Dravet Ch. et al. eds Epileptic syndromes in infancy, childhood and adolescence 2nd ed London: John Libbey & Company 1992:75-88. Dalla BB. Fontana E. Sgro Y. et al Myoclonic epilepsy in nonprogressive encephalopathies In Roger J. Bureau M. Dravet Ch. et al. eds Epileptic syndromes in infancy, childhood and adolescence 2nd ed London John Libbey cV. Company 1992:89-90.
Doose H Myoclonic astatic epilepsy of early childhood In: Roger J. Bureau M. Dravet Ch. et al. eds Epileptic syndromes in infancy, childhood and adolescence 2nd ed London: John Libbey & Company 1992 I 15-112
Brodıe
MJ
. Felbamate: a new antıepıleptıc drug Lancet 1993.341 1445-0
Sofia RD. Kramer L. Perhach JL. et al Felbamate Epilepsy Res 1991 ;3(supp]) I 03-8 Fisher RS Emerging antiepileptic drugs Neurology I 99 3;43i suppl .5 ): 12-7. Graves NM. Ludde TM. Holmes GB. et al Pharmacokinetics of felbamate. a novel antiepileptic drug application of mixed-effect
8
9
10
modeling to clinical trials Pharmacotherapy
' nvo o 17 2-0
(Fueıst RH. et al Effect •y ' •• and carbama '.epsi1
scrim, con- • • -• epilepsia |989.?o 22^-'' Leppik I i 1.'ıpk'ibeı<.' H.I Felbamate In Resor SR. Kuti H .'i.K The medic.ıl treatment of •.-pibpsv New York Marcel Dekkei. |0»2-(>S5-
'HieiHloie Wil Raiibeuas RF. Porter RJ. et al
Felbamate: a clinical trial for complex partial
seizures. Epilepsia 1991;32:392-7. 15. Chadwick D Gabapentin Epilepsy Res
1991.3ı
suppl)
: 183-4 lo Chadwick D Gabapentin. Lancet 1994.343: 89-
lM
17 Richens A Clinical pharmacokinetics of gabapentin In Chadwick D. ed New trends in epilepsy management: the role of gabapentin. International congress and symposium series . New York Royal Society of medicine services 1^)93:41-40
IS Harden CL New antiepileptic drugs Neurology
1004.44 787-95. 19 IJk Gabapentin study group. Gabapentin in
partial epilepsy Lancet 1990.335; 1 14-7 20. US Gabapentin study group no 5. Gabapentin as
add-on therapy in refractory partial epilepsy a
double blind placebo controlled parallel group
study Neurology 1993.43:2292-8
21 Chadwick D Gabapentin In: Pedley T A. Meldrum BS. eds Recent advances in epilepsy. New York Churchill Livingstone 199121 1-21
22 Foot M. Wallace J. Gabapentin Epilepsy Res I 991.3( suppl ): 109-14
23 Richens A Pharmacology and clinical pharmacology of vigabatrm. Child Neurology 1'»9 I.o( suppl. 1-7-10
24 Gram L. Larsson OM. Johnson A. et al Experimental studies of the influence of vigabatrm on the GABA system Br J Clin Pharmacology I 989.27t suppl ) I >-7
25 Arteaga R. Herran/ JL. Yaldi/.an EM. et al Vigabatrm relationship between dosage, plasma concentrations, platelet GABA transaminase inhibition and seizure reduction in epileptic children Epilepsia I 002.3 V92 î-3 I
20. Rev E. Pons G. Olive G \ igabatnn cluneals phai macokinetics Clin Pharmacokmet
1992.2 î 2o7-27S
27 Agostı R. Yaşargıl G. Eglı M. et al. Neuropathology of a human hippocampus following long-term treatment with vigabatrm lack of niicrovacoules Epilepsy Res I99();2 loo-70
28 Mumford .IP. Dam M Meta-analysis of Euıopean plas _d 'indies of vigabatrm m drug resist.i'- .pik'p. 1 <"' Pharmacology |9Sli.27( suppl i K.i -
29 Schlecter ps Vıgabatiıi. !;. MAIMIUS F;^ I^M -RS eds Nev\ Antic- i >r. • ı r -John Libbey. K>8ı> "i.^,
1 l«
.lourmi! ol"l'ur»nt ()/:>' "V i e tl ir u I ( enter 2( 1): 1995
Karabiber ve ark.
Çocuk/ardaki tedaviye dirençli konvülziyonlardayeni antiepıleptik ilaçlar
30. Herranz JL, Arteag R, Forr İN , et al. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurology 1991; 6(5uppl): 52-9.
31 Jaeken J GABA in other neurologic disorders: Spasticity of metabolic origin. Epilog 1992;2:4.
32. Tartara A, Manni R. Galimberti CA , et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurolscand 1992; 86: 247-51.
33 Sabers A, Gram L Pharmacology of vigabatrin Pharmacol Toxicol 1992, 70: 237-43.
34. Kuntzer TK, Bogousslovsky J, Loiseau P. New drug treatments in epilepsy. Eur Neurol 1994; 34:4-10.
35. Yuen AW. Lamotrigine. Epilepsy Res. 1991; 3(suppl): 115-23.
36. Brodie MJ. Lamotrigine. Lancet 1992; 339:1397¬400
37. Meldurum BS. Pharmacology and mechanism of
action of Lamotrigine. In: Reynold EH (ed). Lamotrigine-A New Advance in the treatment of Epilepsy London: Roy Soc Med Serv Ltd, 1993:5-14.
38. Peck AW. Clinical pharmacology of lamotrigine Epilepsia I991;32(suppl.);9-12.
39. Battino D, Buti D, Croci D, et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics 1993;24:332-6.
40. Dren AT; Wonible GP, Yau MK, et al. Placebo-controlled clinical studies demonstrating the efficacy and safety of lamotrigine as add-on therapy in patients with partial seizures (abstract). Epilepsia 1992;33(suppl.3):81.
41 Risner ME and The Lamictal Study Group. Multicenter. double-blind, placebo-controlled, add-on, crossover study of lamotrigine in epileptic outpatients with partial seizures. Epilepsia 1990,31:619.